CH
抗体药类似物
Research Grade Sonelokimab
All
  • CatalogTD-HS856086
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsBispecific,Trivalent,M-1095,MSB-0010841,CAS:1414386-05-2
  • Specification
    1mg
  • Prices
    ¥询价
Customized service consulting

Research Grade Sonelokimab


Catalog No. TD-HS856086
Species reactivity Human
Applications Research Grade Biosimilar
Host species Humanized
Isotype VH-VH'-VH
Expression system Mammalian Cells
Clonality Monoclonal
Target CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, IL17F, Interleukin-17F, IL-17F, Cytokine ML-1, ALB, Albumin
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession Q16552 & Q96PD4 & P02768
Form Liquid
Storage buffer 30mM Histidine ,pH5.8,10% sucrose,0.02% Tween80
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names Bispecific,Trivalent,M-1095,MSB-0010841,CAS:1414386-05-2
Background Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis.
Note For research use only. Not for use in clinical or therapeutic applications.